Dorsey Wright & Associates Makes New Investment in United Therapeutics Corporation $UTHR

Dorsey Wright & Associates bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 5,128 shares of the biotechnology company’s stock, valued at approximately $2,499,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Avoro Capital Advisors LLC lifted its holdings in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Wellington Management Group LLP grew its stake in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC grew its stake in United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after buying an additional 295,221 shares during the last quarter. Janus Henderson Group PLC increased its position in United Therapeutics by 75.1% in the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after buying an additional 341,383 shares during the period. Finally, Darwin Global Management Ltd. acquired a new stake in United Therapeutics in the third quarter worth $317,617,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $536.59 on Friday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The stock has a market cap of $22.78 billion, a price-to-earnings ratio of 19.81, a PEG ratio of 1.80 and a beta of 0.57. The business has a fifty day moving average of $565.37 and a 200-day moving average of $523.32.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.63 earnings per share. On average, equities research analysts predict that United Therapeutics Corporation will post 26.84 EPS for the current year.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,540,358.40. The trade was a 34.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 644,468 shares of company stock worth $364,004,497. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.